Marco Ruiz Andia, MD
Hematology & Oncology · Miami, FLNPI 1356334171
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,475 of the $28,463 with a category attached, or 79.0%. 15 manufacturers reported payments, led by Seagen Inc. at 39.6% of the total. Reporting peaked in 2023 at $14,520 and has fallen 52.1% since, to $6,953 in 2025.
Across 42 payments — averaging $677.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$11K
- Bristol Myers Squibb$6K
- Johnson & Johnson$4K
- CTI Biopharma Corp.$3K
- Karyopharm Therapeutics Inc.$3K
- Insmed, Inc.$130
- plus $479 from 9 others
Across 7 payments — averaging $16,687 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$100K
- Bristol Myers Squibb$14K
- E.r. Squibb & Sons, L.L.C.$2K
- Genentech, Inc.$1K
What the payments were for
- Consulting fees$22,47579%
- Travel & lodging$4,68916%
- Food & beverage$1,1994%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 8 | $11,266 |
| Bristol Myers Squibb | 6 | $6,449 |
| Johnson & Johnson | 10 | $4,052 |
| CTI Biopharma Corp. | 1 | $3,200 |
| Karyopharm Therapeutics Inc. | 2 | $2,888 |
| Insmed, Inc. | 1 | $130 |
| Sanofi | 1 | $126 |
| Incyte Corporation | 1 | $85 |
| Astellas Pharma US Inc | 3 | $60 |
| Daiichi Sankyo Inc. | 2 | $56 |
| Gilead | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Sobi, Inc | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Adaptive Biotechnologies Corporation | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,463 in reported general payments places this provider in the 75th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 12 | $196,670 |
| ErtapenemErtapenem Sodium | 17 | $5,664 |
| CeftriaxoneCeftriaxone Sodium | 28 | $1,360 |
| Acyclovir | 22 | $492 |
| Sodium Chloride0.9 % Sodium Chloride | 22 | $477 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Miami
- Steven FeinMiami$1M
- Srikanth NagallaMiami$639K
- Neil NagovskiMiami$530K
- Carl LandgrenMiami$517K
- Raja MudadMiami$422K
- George NahasMiami$364K
- Fernando de ZarragaMiami$333K
- Mikkael SekeresMiami$278K
- Krishna KomanduriMiami$187K
- Estelamari RodriguezMiami$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.